Propranolol: Clinical Overview
Primary Indication
Propranolol is the first-line treatment for infantile hemangiomas (IH) requiring systemic therapy, with a 95% expected clearance rate compared to 43% for oral steroids and 6% for no treatment 1. It has replaced corticosteroids as the gold standard for threatening IH and received FDA approval specifically for proliferating infantile hemangiomas in 2014 1.
Specific Indications for Treatment
Propranolol should be initiated for 2:
- Vision-threatening periocular hemangiomas (risk of amblyopia, refractive errors, strabismus)
- Airway hemangiomas with actual or potential compromise (96.3% airway clearance rate) 3
- Nasal hemangiomas causing obstruction
- Lip hemangiomas causing functional impairment or disfigurement
- Auditory canal involvement with recurrent infection
- Ulcerated hemangiomas where topical treatment is inappropriate or ineffective
- Risk of permanent disfigurement
- Spinal cord compression
- Liver hemangiomas with cutaneous involvement (in collaboration with specialists)
Dosing Regimens
Standard Uncomplicated Cases
Start at 1 mg/kg/day and advance to a maintenance dose of 2 mg/kg/day 2. Recent evidence supports initiating directly at 2 mg/kg/day without increased adverse events 4, though guidelines remain conservative.
- Starting dose: 1 mg/kg/day (or 0.6 mg/kg twice daily per FDA) 1
- Maintenance dose: 2-3 mg/kg/day divided into 2-3 daily doses 1
- Optimal dose: 3 mg/kg/day for 6 months showed superior outcomes (60% complete resolution vs 4% placebo) 1
- Maximum dose: 3 mg/kg/day for non-responders 2
- Minimum interval between dose increases: 24 hours 2
Special Populations
PHACE Syndrome (segmental facial hemangiomas):
- Start at 0.5 mg/kg/day before brain MRI/MRA 2
- Obtain MRI/MRA of head and neck before full-dose propranolol 1
- Require ECHO and ECG interpreted by pediatric cardiologist 2
- If arterial stenosis/agenesis present, consult pediatric neurology for dosing 2
- Use lowest effective dose, titrate slowly, divide into 3 daily doses 1
Preterm/Low Weight/Comorbidities:
Critical Administration Instructions
Administer propranolol with or after feeding and hold doses during diminished oral intake or vomiting to prevent hypoglycemia 1. This is a strong recommendation (Grade X) from the American Academy of Pediatrics guidelines.
Treatment Duration
- Optimal duration: 6 months (superior to 3 months) 1
- Most cases: Can stop at 12 months of age 2
- Majority: Do not need treatment beyond 17 months 2
- Discontinuation: Safe to stop abruptly without gradual weaning 2
- Rebound risk: Greatest when discontinued <12 months of age, especially before 9 months; lowest risk between 12-15 months 1
Contraindications
Absolute 2, 5:
- Hypoglycemic episodes (recent or ongoing)
- Heart block (second or third degree)
- Cardiogenic shock
- Sinus bradycardia and greater than first-degree block
- Bronchial asthma
- Hypersensitivity to propranolol
Relative 2:
- Frequent wheezing (treat in conjunction with pediatrician)
- Blood pressure outside normal range for age
- Heart rate outside normal range for age
Pretreatment Evaluation
Required 2:
- Cardiovascular and respiratory examination by competent practitioner (auscultation, peripheral pulses, abdominal exam for liver enlargement)
Selected Cases Only:
- ECHO: Not routine; needed for PHACE syndrome, cardiac concerns 2
- ECG: Not routine; needed for PHACE syndrome, cardiac concerns 2
- Baseline glucose: Only for patients at hypoglycemia risk (preterm, low weight, faltering growth, neonates, history of hypoglycemia) 2
- MRI/MRA head and neck: For segmental facial hemangiomas (PHACE evaluation) 1, 2
NOT Required 2:
- Routine FBC, renal, liver, or thyroid profiles
Monitoring Parameters
Initial Dose Monitoring
Post-first dose monitoring is NOT routinely needed 2. When observation is performed 2:
- 30 minutes between HR and BP observations
- Total observation period: 2-4 hours
- Evidence shows prolonged monitoring rarely changes management and does not predict future adverse events 6
Ongoing Monitoring
- Routine follow-up: Every 2-3 months for stable patients 2
- BP and HR: Do NOT need monitoring between appointments if infant is well 2
- Dose adjustments: Can be made at clinic visits, by GP, or by parents with written instructions 2
- Clinical photographs: Document baseline and treatment response 2
- Drug dosing card: Recommended to prevent dosing errors 2
Common Pitfalls and Cautions
Hypoglycemia Prevention
- Always give with or after feeding 1
- Hold doses during illness with poor oral intake 1
- Higher risk in preterm, low weight, faltering growth, neonates 2
Ulceration Worsening
- Propranolol can rarely worsen IH ulceration (reduced blood flow causing peripheral ischemia) 2
- If occurs, reduce dose or consider topical timolol 2
PHACE Syndrome
- Critical: Must obtain brain imaging before full-dose propranolol in segmental facial hemangiomas 1, 2
- Risk of stroke if arterial anomalies present 1
Drug Interactions 5
- Calcium channel blockers: Risk of bradycardia, heart failure, cardiovascular collapse (especially verapamil and diltiazem)
- Antiarrhythmics: Additive effects with propafenone, quinidine; reduced lidocaine clearance
- Digitalis: Increased bradycardia risk
- Alcohol: Increases propranolol plasma levels
Anaphylaxis Risk 5
- Patients with severe anaphylactic history may be more reactive to allergens while on beta-blockers
- May be unresponsive to usual epinephrine doses
Adverse Effects
Overall complication rate: 3.7% 3. Most common adverse effects include 7:
- Hypoglycemia
- Hypotension
- Diarrhea
- Reflux
- Cold hands and feet
- Bronchospasm
- Hyperkalemia
- Sleep disturbances (may require dose reduction) 1
No serious cardiovascular events occurred during prolonged monitoring in multicenter study of 783 subjects 6. Mean heart rate decrease from baseline to 2 hours was only -9.24 bpm 6.
Adult Indications (Non-Hemangioma)
For adult cardiovascular indications 5:
- Hypertension: Start 80 mg once daily (extended-release); usual maintenance 120-160 mg once daily; max 640 mg/day
- Angina: Start 80 mg once daily; usual effective range 160 mg once daily; max 320 mg/day
- Migraine prophylaxis: Start 80 mg once daily; usual effective range 160-240 mg once daily
- Hypertrophic subaortic stenosis: 80-160 mg once daily
Key Takeaway
Propranolol at 2-3 mg/kg/day for 6 months is the most effective treatment for infantile hemangiomas requiring systemic therapy, with excellent safety when administered with feeding and doses held during illness 1. The conservative monitoring protocols initially recommended are being revised as evidence shows minimal utility of prolonged cardiovascular monitoring in uncomplicated cases 6.